Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer.
CPT Pharmacometrics Syst Pharmacol. 2021 Mar;10(3):220-229. doi: 10.1002/psp4.12592. Epub 2021 Feb 13.
CPT Pharmacometrics Syst Pharmacol. 2021.
PMID: 33501768
Free PMC article.